Background
15-Keto-13,14-Dihydro-PGF2α (15-k-13,14-d-PGF2α) is derived from PGF2α through the consecutive actions of 15-hydroxy prostaglandin dehydrogenase and prostaglandin 13-reductase. Quantitation of this compound in circulation can be a good index for PGF2α synthesis in tissue. This is a competitive ELISA kit. Usually, urine and tissue culture supernatant can be assayed directly, whereas it should be extracted from plasma prior to analysis.
Assay Priniciple
This is an ELISA for the quantitative analysis of 15-k-13,14-d-PGF2α levels in biological fluid. This test kit operates on the basis of competition between the enzyme conjugate and the 15-k-13,14-d-PGF2α in the sample for a limited number of binding sites on the antibody coated plate. The sample or standard solution is first added to the microplate. Next, the diluted enzyme conjugate is added and the mixture is shaken and incubated at room temperature for one hour. During the incubation, competition for binding sites is taking place. The plate is then washed removing all the unbound material. The bound enzyme conjugate is detected by the addition of substrate which generates an optimal color after 30 minutes. Quantitative test results may be obtained by measuring and comparing the absorbance reading of the wells of the samples against the standards with a microplate reader at 450nm or 650nm. The extent of color development is inversely proportional to the amount of 15-k-13,14-d-PGF2α in the sample or standard. For example, the absence of 15-k-13,14-d-PGF2α in the sample will result in a bright blue color, whereas the presence of 15-k-13,14-d-PGF2α will result in decreased or no color development.
Literature
See this review by Dr. Samar Basu for why 15-k-13,14-d-PGF2α is a unique biomarker of luteolysis and inflammation.
If using urine as a sample it is recommended to run our
Creatinine Assay kit (CR01)
in conjunction with your samples since urinary creatinine levels may be used to normalize the rate of excretion of other analytes. .jpg)
